Serina Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
SER$1.43+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| NET LOSS | $(19,215) | $(11,207) |
| OTHER COMPREHENSIVE LOSS | ||
| Foreign currency translation adjustment | (14) | — |
| COMPREHENSIVE LOSS | (19,229) | (11,207) |
| Net loss attributable to noncontrolling interest | 33 | 66 |
| COMPREHENSIVE LOSS ATTRIBUTABLE TO SERINA | $(19,196) | $(11,141) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.